News

Mimetogen Pharmaceuticals Inc. Announces Positive Top Line Data from Phase II Clinical Trial of MIM-D3 for Dry Eye Disease

Mimetogen Pharmaceuticals Inc. (“Mimetogen”) today announced positive top line data from a Phase II clinical trial with MIM-D3, its lead drug for the treatment of dry eye. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles. Mimetogen is in the process of completing its analysis of the data, and intends to present further details at a future medical conference.
Continue reading →

Milestone Pharmaceuticals Announces $13 Million Equity Financing

Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing. The round is led by Pappas Ventures, the Business Development Bank of Canada (BDC), and GO Capital. Other participating investors are Fonds de solidarité FTQ (FSTQ), and the company’s previous investors, iNovia Healthcare Ventures, who played a key role during the Company’s founding and was the lead investor in the earlier rounds, and Fonds Bio-Innovation.
Continue reading →

Medwell Capital Announces that Mimetogen Pharmaceutical Inc. Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease

Medwell Capital Corp. (“Medwell”) (TSX-V: MWC) today announced that Mimetogen Pharmaceuticals (“Mimetogen”) completed patient recruitment in its phase II clinical trial of MIM-D3 for dry eye disease. A total of 150 patients have been enrolled in the trial with results expected in the second half of 2011. Under the terms of the agreement announced on February 25, 2011, Medwell will advance a second tranche of funds pursuant to its $2,000,000 financing commitment.

Continue reading →